ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com
A World Leader in Therapeutics and
Diagnostics Targeting Amyloid Diseases
 |
|
The world-wide number of Alzheimer's patients is expected to grow from 16 million to 21 million by 2010. The Alzheimer's disease drug market is expected to grow by 15 percent annually for the next five years. This drug market generated more than $1.3 billion in 2004 in the U.S. alone, and is expected to reach $5.5 billion by 2009.
The global market for Parkinson's disease drug therapies is nearly $3 billion a year and growing. This includes $720 million in the United States. Approximately one percent of the population over the age of 65 is estimated to suffer from Parkinson's disease. In the US about 1.5 million people suffer from this disease. As with Alzheimer's disease, our aging population will give rise to a steadily growing number of people who suffer from Parkinson's disease.
The prevalence of type 2 diabetes in the United States, Europe, and Japan continues to grow at an alarming rate. The type 2 diabetes drug market is expected to reach US $2.5 billion in 2010. ProteoTech's approach to the treatment of this disease allows us to participate in another multi-billion dollar therapeutic market. April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere™ for treatment of Parkinson's disease. March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009 February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference August 07, 2008 ProteoTech's Exebryl-1® enters human clinical trials for the treatment of Alzheimer's Disease July 29, 2008 Exebryl-1® Phase I human clinical trial for Alzheimer's disease commences July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL. May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1® May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research April 28, 2008 ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease
|
 |
